Patents/Inventors

Pablo Umana

WollerauCH19 patents

20 Patents

US124418122025
Methods of Treating Cancer by Administering Tumor Necrosis Factor (TNF) Family Ligand Trimer-containing Antigen-binding Molecules
Hoffmann-la Roche Inc.
0 cites
US123917572025
Bispecific Antibodies Specific for PD1 and TIM3
Hoffmann-la Roche Inc.
0 cites
US122864862025
Anti-fap Antibodies and Methods of Use
Roche Glycart AG
0 cites
US122811532025
Combination Therapy with Targeted 4-1BB (CD137) Agonists
Hoffmann-la Roche Inc.
0 cites
US122757942025
Bispecific Antigen Binding Molecules Comprising Anti-fap Clone 212
Hoffmann-la Roche Inc.
0 cites
US122583712025
Stabilized Immunoglobulin Domains
Hoffman-la Roche Inc.
0 cites
US122409112025
Bispecific Antibodies Specific for OX40
Hoffmann-la Roche Inc.
0 cites
US122028702025
Antigen Binding Molecules Comprising a Trimeric TNF Family Ligand and Encoding Polynucleotides Thereof
Hoffmann-la Roche Inc.
0 cites
US121395532024
T Cell Activating Bispecific Antigen Binding Molecules
Hoffmann-la Roche Inc.
0 cites
US121039822024
T Cell Activating Bispecific Antigen Binding Molecules
Hoffmann-la Roche Inc.
0 cites
US120654782024
Her2-targeting Antigen Binding Molecules Comprising 4-1BBL
Hoffmann-la Roche Inc.
0 cites
US120233682024
Immunoconjugates
Hoffmann-la Roche Inc.
0 cites
US119936422024
Trivalent, Bispecific Antibodies
Hoffmann-la Roche Inc.
0 cites
US119524212024
Bispecific Antibodies Against CD3EPSILON and ROR1
Bristol-myers Squibb Company
0 cites
US118650822024
Combination Therapy of Pd-1-targeted IL-2 Variant Immunocytokines and Antibodies Against Human PD-L1
Hoffmann-la Roche Inc.
0 cites
US118277112023
Antibodies Binding to NKG2D
Hoffmann-la Roche Inc.
0 cites
US117878732023
Bispecific HER2 Antibodies and Methods of Use
Hoffmann-la Roche Inc.
0 cites
US117809192023
Bispecific Antigen Binding Molecules Targeting OX40 and FAP
Hoffmann-la Roche Inc.
0 cites
US116393972023
Bispecific Antibodies Specific for T-cell Activating Antigens and a Tumor Antigen and Methods of Use
Roche Glycart AG
0 cites
US116135872023
Combination Therapy of T Cell Activating Bispecific Antigen Binding Molecules and PD-1 Axis Binding Antagonists
Hoffmann-la Roche Inc.
0 cites